Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
0 ratings in the last 12 months
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.